Imugene Statistics

Total Valuation

Imugene has a market cap or net worth of AUD 75.56 million. The enterprise value is 66.40 million.

Market Cap	75.56M
Enterprise Value	66.40M

Important Dates

The last earnings date was Thursday, February 26, 2026.

Earnings Date	Feb 26, 2026
Ex-Dividend Date	n/a

Share Statistics

Imugene has 321.52 million shares outstanding. The number of shares has increased by 18.24% in one year.

Current Share Class	321.52M
Shares Outstanding	321.52M
Shares Change (YoY)	+18.24%
Shares Change (QoQ)	+32.93%
Owned by Insiders (%)	8.52%
Owned by Institutions (%)	4.49%
Float	266.55M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	19.16
PB Ratio	1.80
P/TBV Ratio	5.00
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

EV / Earnings	-1.13
EV / Sales	16.83
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	-1.11

Financial Position

The company has a current ratio of 1.78, with a Debt / Equity ratio of 0.12.

Current Ratio	1.78
Quick Ratio	1.02
Debt / Equity	0.12
Debt / EBITDA	n/a
Debt / FCF	-0.08
Interest Coverage	-511.26

Financial Efficiency

Return on equity (ROE) is -111.29% and return on invested capital (ROIC) is -58.76%.

Return on Equity (ROE)	-111.29%
Return on Assets (ROA)	-39.22%
Return on Invested Capital (ROIC)	-58.76%
Return on Capital Employed (ROCE)	-119.71%
Weighted Average Cost of Capital (WACC)	16.91%
Revenue Per Employee	262,940
Profits Per Employee	-3.90M
Employee Count	15
Asset Turnover	0.04
Inventory Turnover	n/a

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -80.80% in the last 52 weeks. The beta is 2.48, so Imugene's price volatility has been higher than the market average.

Beta (5Y)	2.48
52-Week Price Change	-80.80%
50-Day Moving Average	0.29
200-Day Moving Average	0.34
Relative Strength Index (RSI)	41.64
Average Volume (20 Days)	871,109

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, Imugene had revenue of AUD 3.94 million and -58.50 million in losses. Loss per share was -0.23.

Revenue	3.94M
Gross Profit	3.94M
Operating Income	-59.17M
Pretax Income	-58.50M
Net Income	-58.50M
EBITDA	-46.92M
EBIT	-59.17M
Loss Per Share	-0.23

Full Income Statement

Balance Sheet

The company has 14.14 million in cash and 4.98 million in debt, giving a net cash position of 9.16 million or 0.03 per share.

Cash & Cash Equivalents	14.14M
Total Debt	4.98M
Net Cash	9.16M
Net Cash Per Share	0.03
Equity (Book Value)	41.87M
Book Value Per Share	0.13
Working Capital	14.15M

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -62.89 million and capital expenditures 3.21 million, giving a free cash flow of -59.68 million.

Operating Cash Flow	-62.89M
Capital Expenditures	3.21M
Free Cash Flow	-59.68M
FCF Per Share	-0.19

Full Cash Flow Statement

Margins

Gross Margin	100.00%
Operating Margin	-1,500.10%
Pretax Margin	-1,483.31%
Profit Margin	n/a
EBITDA Margin	n/a
EBIT Margin	n/a
FCF Margin	n/a

Dividends & Yields

Imugene does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-18.24%
Shareholder Yield	-18.24%
Earnings Yield	-77.43%
FCF Yield	-78.98%

Stock Splits

The last stock split was on July 2, 2025. It was a reverse split with a ratio of 0.0294117647.

Last Split Date	Jul 2, 2025
Split Type	Reverse
Split Ratio	0.0294117647

Scores

Imugene has an Altman Z-Score of -6.99 and a Piotroski F-Score of 1. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	-6.99
Piotroski F-Score	1